Format

Send to

Choose Destination
See comment in PubMed Commons below
Scand Cardiovasc J. 2012 Feb;46(1):23-31. doi: 10.3109/14017431.2011.624195. Epub 2011 Oct 24.

Differential effects of metoprolol and atenolol to neuropeptide Y blockade in coronary artery disease.

Author information

  • 1Department of Cardiology, Oslo University Hospital, Rikshospitalet, Nydalen, Oslo, Norway. lars.gullestad@medisin.uio.no

Abstract

OBJECTIVE:

To explore possible differential effects between metoprolol and atenolol in patients with coronary artery disease.

DESIGN:

The study was randomized, double blind, two-way crossover with the Y1 antagonist AR-H040922 given as IV infusion for 2 h or placebo. Most patients were treated with metoprolol or atenolol. In a post hoc analysis we compared the hemodynamic response to exercise of the Y1 antagonist in patients on metoprolol (n = 16) and atenolol (n = 5), and assessed respiratory sinus arrhythmia (RSA), an indirect measurement of cardiac vagal activation, in the placebo phase in patients on metoprolol (n = 26) and on atenolol (n = 24).

RESULTS:

1) The Y1 antagonist reduced the systolic blood pressure rise during and after exercise during atenolol, but not during metoprolol, while heart rate and maximal load were similar with the two beta-blockers and not affected by the Y1 antagonist. 2) At equal heart- and respiration-rate 7-8 min after exercise the RSA was significantly lower in atenolol than in metoprolol patients, while no difference was seen at rest before exercise.

CONCLUSION:

These findings from this hypothesis generating study indicate that peripheral effects of NPY contribute less to cardiovascular stress reactions in patients on metoprolol than in those on atenolol.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Write to the Help Desk